Brokers Set Expectations for Kadmon Co.’s Q2 2018 Earnings (KDMN)

Kadmon Co. (NYSE:KDMN) – Research analysts at Jefferies Group reduced their Q2 2018 earnings per share estimates for Kadmon in a report released on Wednesday, May 9th. Jefferies Group analyst B. Amin now expects that the company will post earnings of ($0.26) per share for the quarter, down from their previous forecast of ($0.24). Jefferies Group has a “Buy” rating and a $16.00 price target on the stock. Jefferies Group also issued estimates for Kadmon’s Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.22) EPS, FY2018 earnings at ($1.00) EPS, FY2019 earnings at ($1.10) EPS, FY2020 earnings at ($1.15) EPS, FY2021 earnings at ($1.21) EPS and FY2022 earnings at ($0.32) EPS.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $2.67 million.

Several other research analysts have also commented on KDMN. Zacks Investment Research lowered Kadmon from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Piper Jaffray reiterated a “positive” rating and set a $9.00 price target (up previously from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Friday, March 9th. Finally, ValuEngine upgraded Kadmon from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Kadmon currently has a consensus rating of “Hold” and an average target price of $11.55.

Shares of Kadmon opened at $3.70 on Monday, MarketBeat Ratings reports. The firm has a market capitalization of $312.03 million, a price-to-earnings ratio of -2.61 and a beta of 3.97. Kadmon has a fifty-two week low of $2.05 and a fifty-two week high of $5.86.

Several hedge funds and other institutional investors have recently bought and sold shares of KDMN. Citadel Advisors LLC increased its position in shares of Kadmon by 181.3% during the 1st quarter. Citadel Advisors LLC now owns 49,500 shares of the company’s stock worth $210,000 after purchasing an additional 31,906 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Kadmon during the 1st quarter worth about $377,000. Tibra Equities Europe Ltd acquired a new stake in shares of Kadmon during the 1st quarter worth about $647,000. Spark Investment Management LLC increased its position in shares of Kadmon by 55.5% during the 1st quarter. Spark Investment Management LLC now owns 373,000 shares of the company’s stock worth $1,585,000 after purchasing an additional 133,200 shares during the last quarter. Finally, Sphera Funds Management LTD. increased its position in shares of Kadmon by 35.5% during the 1st quarter. Sphera Funds Management LTD. now owns 1,490,000 shares of the company’s stock worth $6,333,000 after purchasing an additional 390,000 shares during the last quarter. Institutional investors and hedge funds own 61.75% of the company’s stock.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply